Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Gastric Cancer

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced today that the first patient has been dosed in a phase III clinical trial (ORIENT-16) that is to evaluate...

Access to Care, Knowledge About Genetic Testing and Clinical Trials Identified as Key Issues in Landmark Survey of Neuromuscular Community

ONEVoice, a landmark survey funded by the Muscular Dystrophy Association (MDA) and conducted by Edge Research, has identified key areas of concern among more than 3,000 respondents – 2,430 adults with neuromuscular disease and 932 caregivers/family members – as well...
SEARCH FOR STUDIES